News brief­ing: In­tel­lia hits clin­ic with CRISPR ther­a­py; Vi­for con­tin­ues to spend, pay­ing up to $340M for DGF pro­gram

An­oth­er CRISPR ther­a­py has en­tered the clin­ic. In­tel­lia Ther­a­peu­tics, the Cam­bridge gene edit­ing biotech, an­nounced to­day that they dosed their first pa­tient with a ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER